Rezum, Aquablation, Laser enucleation and prostatic stents: Have they already changed invasive prostatic treatment paradigms?
The objective of this lecture is to review what we can expect from the new minimal invasive procedures from an independent and critical point of view. What is the ideal patient, the incidence of complications and re-operation rates in the real world?
For how long should medical treatment of LUTS be maintained in men in an era of minimal invasive prostatic surgical treatments?
Do we maintain the medical treatment too long? Prolonged medical treatment may lead to operate patients at older ages and with poorer bladder function. Should minimal invasive procedures, which already demonstrate efficacy and safety, come into play earlier?
Does the preservation of ejaculation form a value-based health care variable in prostatic invasive treatments or should we look for others?
How important is the preservation of ejaculation for our patients, when balancing other parameters at the moment of surgical decision?
Why do so many patients remain on pharmacotherapy after surgery for benign prostate disease?
A large number of patients maintain medical treatment after BPE intervention. Does this result from an incorrect diagnosis (DO, DU, nocturia), incomplete removal of prostatic tissue or is the consequence of a delayed treatment that caused bladder impairment?